Stockreport

H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential [Yahoo! Finance]

Rani Therapeutics Holdings, Inc. - Class A  (RANI) 
PDF Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes that the company has 3 major value driv [Read more]